SCHEMBL8937258

SCHEMBL8937258

COc1cc(-c2cccc(C=CC(=O)O)c2)cc(OC)c1OC

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.66
ALDH1A1 P00352 2/20 0.66
HPGD P15428 2/20 0.66
HSD17B10 Q99714 2/20 0.66
HTR1A P08908 2/20 0.66
HTR2C P28335 1/20 0.66
ABCB1 P08183 2/20 0.60
TNFRSF1A P19438 2/20 0.57
ALOX15 P16050 1/20 0.56
MAPK1 P28482 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
PKM P14618 2/20 0.54
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA3 P07451 1/20 0.54
CSNK2A2 P19784 1/20 0.54
CA4 P22748 1/20 0.54
CA6 P23280 1/20 0.54
CA5A P35218 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937480 1.00 KDM4E (0.66) KDM4EALDH1A1HPGDHSD17B10HTR1A
SCHEMBL8937255 1.00 KDM4E (0.66) KDM4EALDH1A1HPGDHSD17B10HTR1A
SCHEMBL8937421 0.87 KDM4E (0.70) KDM4EALDH1A1HPGDHSD17B10HTR1A
SCHEMBL8937324 0.87 KDM4E (0.70) KDM4EALDH1A1HPGDHSD17B10HTR1A
SCHEMBL8937327 0.87 KDM4E (0.70) KDM4EALDH1A1HPGDHSD17B10HTR1A
SCHEMBL8999239 0.83 MAOB (0.58) KDM4EALDH1A1HPGDHTR1AABCB1
SCHEMBL28500089 0.81 FOS (0.61) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL8937301 0.81 KDM4E (0.60) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL8937305 0.81 KDM4E (0.60) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL8937431 0.81 KDM4E (0.60) KDM4EALDH1A1HPGDHSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed